Gaboxadol - Ovid Therapeutics

Drug Profile

Gaboxadol - Ovid Therapeutics

Alternative Names: LU-02030; LU-2-030; MK-0928; OV-101; THIP

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Max Planck Institute of Psychiatry
  • Developer Lundbeck A/S; Ovid Therapeutics
  • Class Anaesthetics; Analgesics; Anorectics; Antidepressants; Antiepileptic drugs; Hypnosedatives; Isoxazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Angelman syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Angelman syndrome
  • Phase I Fragile X syndrome
  • Preclinical Epilepsy
  • Discontinued Insomnia; Major depressive disorder

Most Recent Events

  • 28 Nov 2017 Ovid Therapeutics completes a phase I trial in Angelman syndrome and Fragile X syndrome (In adolescents) in USA (NCT03109756)
  • 28 Nov 2017 Safety and pharmacokinetics data from a phase I trial in Angelman syndrome and Fragile X syndrome (In adolescents) released by Ovid Therapeutics
  • 16 Oct 2017 Pharmacodynamics data from a preclinical study in Fragile X syndrome released by Ovid therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top